Published online Apr 27, 2022. doi: 10.4254/wjh.v14.i4.766
Peer-review started: November 8, 2021
First decision: December 12, 2021
Revised: January 4, 2022
Accepted: March 7, 2022
Article in press: March 7, 2022
Published online: April 27, 2022
Processing time: 164 Days and 12.8 Hours
ST-Elevation myocardial infarction (STEMI) remains a significant cause of morbidity and mortality globally. A particularly susceptible population are patients with liver cirrhosis.
This study aims to find what factors predicted morbidity and mortality in patients with liver cirrhosis that may need to undergo interventional management for STEMI related cardiogenic shock.
We aim to identify predictors of morbidity and mortality in patient with liver cirrhosis that undergo interventional management for STEMI related cardiogenic shock. We aim to find the effect of liver cirrhosis on mortality, length of stay, and hospital costs in patients with STEMI related cardiogenic shock.
We conducted a retrospective review on the national inpatient sample 2017. Using the student t-test and propensity-matched multivariate logistic regression, we were able to find the P value and odds of mortality.
We find that patients with liver cirrhosis have significantly higher morbidity and mortality rates than those without liver cirrhosis. They are also susceptible to adverse outcomes when undergoing interventional management.
Physicians must optimize patients with liver cirrhosis before any interventional procedure. Patients with mild cirrhosis seemed to have better outcomes than patients with moderate-severe liver cirrhosis.
This research will help build the framework for future studies to study this topic further. The goal would be to identify a scoring system that would allow physicians to ascertain which patients would be safely able to undergo interventional management and which would not. As of now, it is mostly under clinical judgment.